A phase IIb study investigating testosterone undecanoate [LPCN 1111] in men with hypogonadism
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2016
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism
- Focus Adverse reactions
- 26 Sep 2016 Status changed from recruiting to completed according to a Lipocine media release.
- 26 Sep 2016 Results published in a Lipocine media release.
- 04 Jan 2016 Status changed from planning to recruiting, according to a Lipocine media release.